Sandostatin

PreclinicalSmall molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sandostatin is one of 35 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

AcromegalyActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

AcromegalyPreclinical

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Ablavar

LLantheus Medical Imaging

Preclinical

2 7

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 8

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2051

Recruiting

Acromegaly

NCT03158090

Clinical

Trials by Indication[1]

Adult Subject1 trial

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05761431·56 enrolled

Surgery1 trial

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

Unknown status·—·Phase 4·NCT02427295·1 enrolled

Acromegaly1 trial

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Recruiting·GGinkgo Leaf Center for Rare Disorders··NCT03158090·1,965 enrolled

Prostate Cancer1 trial

Sandostatin for Patients With Androgen Independent Prostate Cancer

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00510224·13 enrolled

Statin1 trial

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 4·NCT04140409·10 enrolled

1 more indication

Breast Cancer1 trial

Stress, Diurnal Cortisol, and Breast Cancer Survival

Completed·SStanford University··NCT00226967·115 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Sandostatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sandostatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sandostatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sandostatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2051

Trials by Indication[1]

Adult Subject1 trial

Surgery1 trial

Acromegaly1 trial

Prostate Cancer1 trial

Statin1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News